Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes

Aims/hypothesis Interfering with the activation of receptor for AGE (RAGE) by using a soluble form of the AGE receptor (sRAGE) prevents or ameliorates the vascular complications of diabetes in experimental studies. Relatively little is known about factors that influence endogenous circulating sRAGE...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2007-09, Vol.50 (9), p.1819-1825
Hauptverfasser:	Tan, K. C. B, Chow, W. S, Tso, A. W. K, Xu, A, Tse, H. F, Hoo, R. L. C, Betteridge, D. J, Lam, K. S. L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Advanced glycation end-products Age Aged Biological and medical sciences Blood Glucose - metabolism Blood Pressure Body Mass Index Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Double-Blind Method Drug dosages Endocrine pancreas. Apud cells (diseases) Endocrinopathies Enzyme-Linked Immunosorbent Assay Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Glucose Glyburide - therapeutic use Humans Hypoglycemic Agents - therapeutic use Kinases Ligands Male Medical sciences Middle Aged RAGE Receptor for Advanced Glycation End Products Receptors, Immunologic - blood Receptors, Immunologic - drug effects Soluble receptor for advanced glycation end-products Thiazolidinedione Thiazolidinediones - therapeutic use Type 2 diabetes mellitus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!